Charles River Labs Intl Stock
Charles River Labs Intl Stock
Charles River Labs Intl gained 0.600% compared to yesterday.
The stock is an absolute favorite of our community with 23 Buy predictions and no Sell predictions.
With a target price of 165 € there is a slightly positive potential of 9.49% for Charles River Labs Intl compared to the current price of 150.7 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 0.600% | -0.597% | -1.803% | 70.305% | -13.235% | -19.224% | -41.938% |
| Ligand Pharmaceuticals | 1.140% | -2.235% | -4.372% | 90.217% | 5.422% | 153.623% | 34.564% |
| United Therapeutics | 0.760% | -0.429% | 3.615% | 96.730% | 14.042% | 134.957% | 184.971% |
| Ionis Pharmaceuticals Inc. | 1.150% | -1.110% | -0.804% | 169.073% | -5.650% | 87.980% | 80.264% |
Comments
Charles River Laboratories International (CRL) had its "outperform" rating reaffirmed by Evercore Inc.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat